At least 10 drug developers, including ETHZilla, Sonnet BioTherapeutics, and Sharps Technology, have unveiled similar crypto pivots.
Caliber’s stock has swung sharply since adopting its Chainlink-focused treasury strategy, soaring in August before falling back under $4.